Measurement of active coagulation factors in Autoplex®-T with colorimetric active site-specific assay technology

Thrombosis and Haemostasis

Volumn 80, Issue 5, 1998, Pages 811-815

  Lundblad, Roger L ^a   Bergstrom, Jennifer ^a   De Vreker, Rene ^a   Bray, Gordon ^a   Gomperts, Edward ^a   Baker, Don ^a   Kingdon, Henry S ^a   Mann, Kenneth G ^b   Hartshorn, Jeanette ^c   Jenny, Richard J ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c Haematologic Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9A; GLUTAMYLGLYCYLARGININE CHLOROMETHYL KETONE; KETONE DERIVATIVE; PHENYLALANYLPROLYLARGININE CHLOROMETHYL KETONE; PROCOAGULANT; PROTEINASE; PROTHROMBIN A; STREPTAVIDIN; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; COLORIMETRY; ENZYME ACTIVE SITE; IMMUNOASSAY; MEASUREMENT; PRIORITY JOURNAL;

EID: 0031797761     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615363     Document Type: Article

References (37)

1. Kurczynski EM, Penner JA. Activated prothrombin complex Concentrate for patients with factor VIII inhibitors. New Eng J Med 1974; 291: 164-7.
2. Melewski DJ, Huebschmann U, Tourbaf K, Ambrus CM, Ambras JL. Thrombogenicity of antihemophiliac preparations with factor VIII bypassing activity. J Med 1981; 12: 89-96.
3. Vinazzer, H. Comparison Between two concentrates with Factor VIII inhibitor bypassing activity. Thromb Res 1982; 26: 21-9.
4. Abildgaard CF, Penner JA, Watson-Williams EJ. Anti-Inhibitor Coagulant Complex(Autoplex) for treatment of Factor VIII inhibitors in hemophilia. Blood 1980; 56: 978-84.
5. Teitel JM. The factor VIII bypassing activity of prothrombin complex concentrates: The roles of Factor VIIa and of endothelial cell tissue factor. Thromb Haemost 1991; 66: 559-64.
6. Sultan Y, Loyer F. In vitro evaluation of factor VIII-bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: Thrombin generation test in the presence of collagen-activated platelets. J Lab Clin Med 1993; 121: 444-52.
7. Bloom AL. Management of factor VIII inhibitors: Evolution and current status. Haemostasis 1992; 22: 268-75.
8. Macik BG. Treatment of factor VIII inhibitors: Products and strategies. Sem Thromb Hemostas 1993; 19: 13-24.
9. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs With inhibitors-benefits and limitations. Sem Hem 1994; 31 (2 Supp 4): 49-52.
10. Williams EB, Krishnaswamy S, Mann KG. Zymogen/enzyme discrimination using peptide chloromethyl ketones. J Biol Chem 1989; 264: 7536-44.
11. Mann KG, Williams EB, Krishnaswamy S, Church W, Giles A, Tracy RP. Active site-specific immunoassays. Blood 1990; 76: 755-66.
12. Williams EB, Mann KG. Peptide chloromethyl ketones as labelling reagents. Methods Enzymol 1993; 222: 503-13.
13. Tracy RP, Jenny R, Williams EB, Mann KG. Active site-specific assays for enzymes of coagulation and fibrinolytic pathways. Methods Enzymol 1993; 222: 514-25.
14. Gordon EM, Ratnoff OD, Jones PK. The Role of augmented Hageman factor (Factor XII) titers in the cold-promoted activation of Factor VII and spontaneous shortening of the prothrombin time in women using oral contraceptives. J Lab Clin Med 1982; 99: 363-69.
15. Schmaier AH, Silverberg M, Kaplan AP Colman RW. Contact activation and Its abnormalities, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 2nd ed. Philadelphia, PA, Lippincott, 1987 p. 18-38.
16. Colman RW, Marder VJ, Salzman EW, Hirsh J. Plasma coagulation factors, in Colman RW, Hirsh J, Marder VJ, Salzman, EW. (eds.): Hemostasis and Thrombosis. Basic Prinicples and Clinical Practice. 3rd ed. Philadelphia, PA, 1994 p. 3-17.
17. Broze GJ, Jr., Majerus PW. Purification and properties of human coagulation Factor VII. J Biol Chem 1980; 255: 1242-7.
18. Butenas S., Mann KG. Kinetics of human Factor VII activation. Biochemistry 1996; 35: 1904-10.
19. Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated Factor VII. Presence in Factor IX concentrate and persistence in circulation after infusion. Blood 1978; 53: 828-37.
20. Hultin MB. Studies of Factor IX concentrate in hemophilia. Blood 1983; 62: 677-84.
21. Jordon RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081-90.
22. Lawson JF, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J. Biol Chem 1993; 268: 767-70.
23. Scully MF. Kinetic considerations in the physiologic control of thrombin and factor Xa. Sem Thromb Hemostas 1992; 18: 218-23.
24. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Therapeut 1994; 55: 638-48.
25. Eichinger S, Mannucci PM, Tradati F, Arbini AA, Rosenberg RD, Bauer KA. Determinants of plasma factor VIIa levels in Humans. Blood 1995; 86: 3021-25.
26. Wildgoose P, Nemerson Y, Hanse LL, Nielsen EE, Glazer E, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
27. Giles AR, Mann KG, Nesheim JE. A combination of factor Xa and phosphatidylcholine-phoshatidylserine vesicles bypasses factor VIII in vivo. Brit. J. Haematol. 1988; 69: 491-7.
28. Wolf DL, Lin PH, Hollenbach S, Wong A, Phillips DR, Sinha U. Procoagulant activity of reversibly acylated human factor Xa. Blood 1995; 86: 4153-7.
29. Lin PH, Laibelman AM, Sinha U. Reversible acylation of Factor Xa as a Potential Therapy for Hemophilia. Thromb Res 1997; 88: 365-72.
30. Friedberg RC, Hagen P-O, Pizzo SV. The Role of Endothelium in Factor Xa Regulation. The Effect of Plasma Proteinase Inhibitors. Blood 1988; 71: 1321-8.
31. Walker FJ, Esmon CT. The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III. Biochem Biophys Res Comm 1979; 90: 641-7.
32. Ellis V, Scully MF, Kakkar VV. Inhibition of prothrombinase complex by plasma proteinase inhibitors. Biochemistry 1984; 23: 5882-7.
33. Fenton JW, II, Fasco, MJ Stackrow AB, Aronson DL, Young AM, Finlayson JS. Human Thrombin. Production, Evaluation and Properties. J Biol Chem 1977; 252: 3587-98.
34. Broze GJ Jr., Majerus PW. Human Factor VII. Methods in Enzymology 1981; 80: 228-37.
35. Di Scipio RG, Kurachi K, Davie EW. Activation of Human Factor IX (Christmas Factor). J Clin Invest 1978; 61: 1528-38.
36. Di Scipio RG, Hermodson MA, Davie EW. Activation of Human Factor X (Stuart Factor) by a Protease from Russell's Viper Venom. Biochemistry 1977; 16: 5253-60.
37. Kurachi K, Chung DW, Hendrickson LE, Davie EW. Amino Acid Sequence of Human Factor Xa, A Blood Coagulation Factor with Four Tandem Repeats That Are Highly Homologous with Plasma Kallikrein. Biochemistr 1986; 25: 2417-24.